Aurobindo Pharma gets USFDA nod for generic cancer drug Bortezomib
PTI, May 3, 2022, 5:08 PM IST
New Delhi: Aurobindo Pharma on Tuesday said its wholly-owned arm Eugia Pharma Specialties Ltd has received final approval from the US health regulator to manufacture and market its generic version of Bortezomib for injection used to treat certain types of cancer.
The approval by the US Food and Drug Administration (USFDA) is for single-dose vial of Bortezomib for injection of strength 3.5 mg/vial, Aurobindo Pharma said in a regulatory filing. The product is the generic version of reference listed drug Velcade of Takeda Pharmaceuticals USA Inc.
The product is being launched immediately, it added.
Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma (cancer of plasma cells) and is also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes), the company said.
The approved product has a market size of USD 1.172 billion for the 12 months ended March 2022, the company said citing IQVIA data.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
World Malaria Day: WHO calls for equitable health access
What role does genetics play in breast cancer? How can genetic testing help with early breast cancer diagnosis?
Father’s diet can affect anxiety in sons, metabolism in daughters: Study in mice finds
Low back pain, depression, headaches main causes of poor health: Study
Surgical options for Parkinson’s disease
MUST WATCH
Latest Additions
Low voter turnout in Karnataka: Only 38.23% cast votes in 14 LS segments during first half of the day
Karnataka Polls: No Modi wave but anti-BJP wave, says CM Siddaramaiah
Cal HC directs NIA to file report on clashes in Murshidabad over Ram Navami celebrations
Bengaluru goes to poll amid heat wave-like situation
Karnataka officials don vibrant sarees to promote voter participation